Key Points
- CEO August Troendle sold 17,610 Medpace shares at an average price of $605.11, generating approximately $10.66 million. He retained 615,802 shares, with the transaction reducing his ownership by 2.78%.
- Medpace reported quarterly EPS of $4.25, exceeding estimates of $3.98, while revenue rose 17.2% year over year to $707.33 million. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
- Analysts have an overall “Hold” rating and a consensus price target of $584.18, despite several target increases. Medpace shares opened at $596.98, compared with a 52-week range of $373.00 to $677.90.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 5,534 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $601.53, for a total transaction of $3,328,867.02. Following the completion of the sale, the chief executive officer owned 633,412 shares in the company, valued at approximately $381,016,320.36. The trade was a 0.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Medpace Stock Down 1.4%
MEDP stock opened at $596.98 on Thursday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The firm has a market capitalization of $16.66 billion, a P/E ratio of 34.99, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15. The company has a fifty day simple moving average of $531.28 and a two-hundred day simple moving average of $491.78.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same period in the previous year, the firm posted $3.10 EPS. The business's quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.
Hedge Funds Weigh In On Medpace
Hedge funds have recently bought and sold shares of the business. Globeflex Capital L P purchased a new stake in Medpace in the second quarter worth $5,806,000. Haverford Trust Co purchased a new stake in shares of Medpace during the second quarter valued at $245,000. Kendall Capital Management bought a new position in shares of Medpace in the second quarter worth about $1,207,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Medpace in the second quarter worth about $228,000. Finally, Quantbot Technologies LP purchased a new position in Medpace in the 2nd quarter worth about $687,000. Institutional investors own 77.98% of the company's stock.
Wall Street Analyst Weigh In
MEDP has been the topic of a number of recent research reports. Mizuho upped their price objective on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Finally, TD Cowen boosted their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $584.18.
Check Out Our Latest Analysis on Medpace
About Medpace
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
